BioMarin Pharmaceutical Inc.

AI-generated fair value estimate for this company.

Method: 10-year two-stage unlevered FCF DCF: about $800M normalized FCF base scaling TTM FCF of $738M for the April 2026 Amicus Therapeutics acquisition and FY2026 revenue guidance of $3.875-3.925B; 10% growth years 1-5; 6% years 6-10; 3% terminal growth; 9% discount rate; less $3.33B net debt post-Amicus; 193.57M shares outstanding.

Reasoning: BioMarin is a profitable, diversified rare-disease biopharma with a durable recurring cash-flow base from its enzyme-replacement franchise and Voxzogo, so a standard multi-stage FCF DCF applies, with growth tracking 10.1% per year analyst consensus revenue growth moderating over time.